News Hub | News Direct

Why You May Want To Consider Linqto As Your Go-To Pre-IPO Investing Platform

Benzinga

By Kyle Anthony, Benzinga Learn how Linqto is bridging the gap to make private equity more accessible and affordable by clicking here! Though Airbnb (NASDAQ: ABNB), Meta Platforms (NASDAQ: META), and Uber (NYSE: UBER) are industry-leading firms with strong consumer brands, their success did not start when they became publicly traded firms but began when they were private entities, backed by private capital. While Initial Public Offerings (IPOs) are viewed as a seminal moment in a company’s history, investors who had pre-IPO ownerships of these companies garnered significant wealth from them before their public listing, and a recent study showed that private companies are 50% more profitable than public companies. Furthermore, according to private equity manager Bain & Company, "public assets have historically commanded "higher average valuation s " than private companies. With more individuals becoming aware of this occurrence, there is a growing interest and desire to engage in private investing. Linqto, a San Jose, California-based firm, recognizes this trend and believes more individuals should be able to access private market opportunities. The company’s mission is to democratize private investing by making it accessible, affordable and liquid for individual investors. Here’s why Linqto may be the ideal platform for individuals considering or seeking out private investments. What Is Linqto’s Overarching Purpose? Linqto's vision is to democratize private investing by making it accessible, affordable, and liquid for individual investors. These attributes are central to Linqto’s platform, empowering investors to engage with private markets meaningfully. Linqto promises to deliver: An inclusive, easy-to-use, secure and fast digital experience on its platform. Private investments at an affordable price: The minimum order is $2500, with subsequent investment amounts being $5,000, and there are no hidden costs. This compares to competitor Charles Schwab’s (NYSE: SCHW) recent announcement that it would launch a self-directed alternative investments platform for qualified individual investors with assets of more than $5 million. Though firms such as Forge Global Holdings (NYSE: FRGE), EquityZen and HIIVE facilitate pre-IPO investing, Linqto says its fee structure is more advantageous to retail investors, especially given that historically such opportunities have required a minimum investment amount of $100,000. Liquidity by maintaining significant holdings for shares of companies on their platform: These shares are sourced from founders, employees and investors at a negotiated price. How Does Linqto Select Investments For Its Platform? Linqto primarily invests in mid to late-stage private companies in the technology industry. Selected firms must generate a minimum revenue amount and have institutional venture capital or private equity investor backing. Leveraging its in-house research expertise and evaluation capabilities, Linqto conducts in-depth due diligence on the firms it includes on its platform as it invests alongside its investors. By investing first and ensuring that Linqto has skin in the game, the firm can streamline the investment process, making it as easy as pointing and clicking to participate in the investment opportunities presented on the platform. Liqnto’s executive leadership team comprises individuals with deep and extensive expertise in venture capital, technology, corporate strategy and innovation, among other specialties. The broader organization reflects various disciplines and professional experiences, collaborating to enhance the platform’s offering and user experience continually. What Are Investors Receiving When They Purchase Shares On Linqto’s Platform? When an investment is made on Linqto’s platform, investors receive the equivalent number of shares in a Special Purpose Vehicle (SPV) managed by Linqto but owned by the investors. The investors are protected against creditors in the event of bankruptcy. The benefit of this approach is that when private equity is sold, the company has the right to refuse that sale. By selling a representation of shares that Linqto owns, it can guarantee an immediate sale to investors without the company having the right to refuse that sale. Furthermore, the SPV structure allows only one investor, Linqto, on the company's cap table, which is desirable to the company as they want to minimize the number of investors on their cap table for funding and regulatory reasons. Is There A Holding Period For Shares Purchased? Linqto has a 90-day holding period. From the date of purchase, members must hold the asset for 90 days before selling and cannot use those shares to purchase another security on the platform. Is Linqto A Financially Regulated Platform? Linqto is a broker/dealer registered with the Securities and Exchange Commission (SEC) and a Financial Industry Regulatory Authority (FINRA) member. The firm also has Alternative Trading System licenses, making it a go-to legal and compliant platform for investors. An ATS is a regulated platform enabling securities trading outside traditional stock exchanges. It allows investors to buy and sell shares in private emerging unicorn companies more quickly and efficiently. A New Avenue For Wealth Generation As demand for private investments grows, Linqto’s platform can help investors broaden their investment opportunities in a turnkey manner. With many companies remaining private for longer, Linqto’s platform is a new avenue through which young investors can gain early, pre-IPO access to companies that could potentially be poised to be industry leaders. To learn more and begin investing with Linqto, click here! Featured photo by Joshua Mayo on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 09:00 AM Eastern Daylight Time

Image

Synergist Technology Partners with Microsoft to Drive Ethical and Compliant AI Innovation

Synergist

Synergist Technology, a leader in AI governance and compliance, announces a strategic partnership with Microsoft, aimed at advancing the development and deployment of compliant AI solutions. By integrating Synergist’s expertise with Microsoft’s robust cloud infrastructure, the partnership seeks to address the growing market demands for ethical and secure AI systems. As the rapid adoption of AI continues to outpace regulatory frameworks, many organizations face significant challenges in deploying AI technologies with accountability. Together, the companies will provide comprehensive AI solutions that help businesses navigate the complex landscape of AI regulations while maximizing the potential of Microsoft’s AI offerings. The partnership is further strengthened by the involvement of key partners, including Pliant Consulting and Maureen Data Systems, which will assist in integrating and enhancing AI solutions for clients. This collaborative effort ensures that customers can navigate the complexities of AI governance with ease and assurance. “With over 700 pieces of proposed regulation at the state and federal level, our partnership with Microsoft represents a significant step forward in our mission to bring responsible AI to every organization,” said Elycia Morris, CEO of Synergist Technology. “By combining our governance and compliance expertise with Microsoft’s advanced technologies, we are creating a powerful synergy that will enable organizations to harness the transformative power of AI while maintaining trust and transparency.” “This partnership enables organizations to confidently leverage AI’s transformative power while adhering to the highest standards of regulatory adherence,” said Vishal Amin, General Manager of Security Solutions, Microsoft. “Microsoft and Synergist have a shared commitment to empower businesses to achieve more through innovation and trust.” Since the inception of the partnership, Synergist has made significant strides in its go-to-market strategy, leveraging Microsoft programs such as the ISV Success Program to expand the reach of its offerings. This strategic collaboration is set to evolve further, with plans to integrate Synergist’s AFFIRM platform into Microsoft’s Marketplace, making it more accessible to businesses worldwide. About Synergist Technology Synergist Technologies is a leader in AI governance and compliance, specializing in enabling ethical and compliant AI innovation through their AFFIRM platform. Their solutions help organizations navigate the complexities of AI regulations, ensuring responsible and effective AI deployment.For more information, visit https://synergist.technology/. Contact Details Julia Worthington synergist@kitehillpr.com

August 29, 2024 09:00 AM Eastern Daylight Time

Benchmark International Releases Global Semiconductor Machinery Manufacturing Industry Report, Spotlighting Market Growth and Key Trends

Benchmark International

Benchmark International, a leader in the mergers and acquisition (M&A) industry, has published its latest Global Semiconductor Machinery Manufacturing Industry Report. This comprehensive analysis provides critical insights into the rapidly evolving semiconductor machinery sector, highlighting growth opportunities, industry challenges, and emerging trends that are reshaping the landscape. As the global demand for semiconductors continues to soar, driven by advancements in artificial intelligence, 5G, and consumer electronics, the semiconductor machinery manufacturing industry is experiencing significant growth. Benchmark International’s report delves into the key factors influencing this sector, from technological innovations to geopolitical developments that are shaping supply chains and market dynamics. Key highlights of the report include: Technological Advancements: The latest advancements in semiconductor machinery, highlighting innovations that are boosting production efficiency and driving next-generation semiconductor development. Market Drivers: An analysis of the rise of AI, IoT, and 5G technologies as key market drivers, significantly increasing the demand for advanced semiconductor machinery. Regional Market Dynamics: Insights into regional dynamics, focusing on the contributions and dominance of key players in North America, Asia-Pacific, and Europe. With semiconductor machinery manufacturing at the forefront of technological innovation, the report serves as an essential resource for industry professionals, investors, and companies looking to stay ahead in a highly competitive market. The report is now available on Benchmark International's website and is part of the firm’s ongoing efforts to provide comprehensive market intelligence to its clients. For more information and to access the full 2024 Global Semiconductor Machinery Manufacturing Industry Report, please visit https://www.benchmarkintl.com/insights/global-semiconductor-machinery-manufacturing-industry-report/ ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

August 29, 2024 09:00 AM Eastern Daylight Time

Image

Landmark Real Estate Lawsuit Just Changed the Rules – This RE Tech Company May Have The Perfect Solution

Benzinga

By Johnny Rice, Benzinga Mike Logozzo, President & COO, and Brent Miller, CFO of reAlpha Tech Corp. (NASDAQ: AIRE), were recently guests on Benzinga’s All-Access. reAlpha Tech Corp. is a real estate technology company developing an end-to-end commission-free homebuying platform. Utilizing the power of AI and an acquisition-led growth strategy, reAlpha’s goal is to offer a more affordable, streamlined experience for those on the journey to homeownership. Mr. Logozzo and Mr. Miller spoke about their exciting new product and how they plan to disrupt the real estate industry. Learn more here: Featured photo by Dillon Kydd on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 08:50 AM Eastern Daylight Time

Video Image

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions

Benzinga

By Kyle Anthony, Benzinga Palatin Technologies (AMEX: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, received the first FDA approval for a melanocortin agent, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, with its product, Vyleesi ® (bremelanotide injection) – and it has big plans for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i (viagra ®, cialis ® ) monotherapy The melanocortin system is a group of hormones, receptors and other molecules in the body that regulate various physiological processes, including skin pigmentation, appetite, energy balance and inflammation. For Palatin Technologies, the melanocortin system has been a source of innovation. The firm leverages its knowledge of the melanocortin system to design therapeutics that directly engage one of the body’s natural pathways to resolve harmful inflammation, providing a novel approach that allows affected tissue time to heal. The Mission Of Palatin Technologies Founded in 1986 by Dr. Carl Spana and other scientists with the initial aim of developing proprietary technologies and drug candidates for large markets with unmet needs, including cardiovascular disease and cancer, the firm has undergone a series of changes over the years. In the early 2000s, Palatin began focusing on the melanocortin system, particularly developing drugs that target melanocortin receptors. The company’s mission is to leverage its unique insight and expertise in the industry and the melanocortin system to develop groundbreaking therapeutics for inflammatory and autoimmune diseases, focusing on ocular conditions, plus obesity and sexual dysfunctions. Maximizing The Capabilities Of The Melanocortin System The melanocortin system is mediated by a family of five related receptors that are essential to the body’s control of inflammation, immune response, metabolism, steroid hormone production and sexual function. As mentioned previously, Palatin Technologies’ current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with an emphasis on ocular diseases, plus obesity and sexual dysfunctions. Palatin Technologies’ therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse intestinal and ocular inflammation in animal models. Current ocular drugs can be limited by drawbacks such as inadequate efficacy, high discontinuation rates and delayed onset of action. These challenges result in a less-than-ideal treatment experience, causing frustration and driving the need for more effective solutions. Melanocortin receptors, which are found on the surface of various cells in the eye and within immune cells in ocular tissue, represent a promising target for melanocortin agonists to offer relief and healing for individuals suffering from ocular diseases. For inflammation and autoimmune diseases, current treatments – including steroids, immune modulators and biologics – largely work by broadly suppressing the immune response. However, these methods can weaken the body's overall immune function, leading to unwanted side effects and raising safety concerns. Melanocortin agonists offer the potential to resolve inflammation without these adverse effects and safety issues associated with immunosuppressants. Palatin Technologies: Success And Product Pipeline Though Vyleesi was Palatin Technologies' first commercial product, the company recently announced several program advancements: Patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity Topline Results Expected Q1 Calendar Year 2025 FDA Confirms Acceptability of Palatin’s Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) MELODY-2 & MELODY-3 Phase 3 Clinical Trials Targeted To Start Later This Calendar Year Topline Results Expected Q4 Calendar Year 2025 Treating Eye Related Diseases As referenced previously, Palatin is exploring using melanocortin agonists for age-related eye diseases. As detailed in the company’s corporate presentation, diseases such as dry eye disease, glaucoma and retinopathies are sizable target markets. Dry eye disease (DED) or keratoconjunctivitis is a multifactorial disorder of the tears and ocular surface. Symptoms include dryness, irritation, redness, discharge and blurred vision. Inflammation plays a prominent role in the development and amplification of the signs and symptoms of DED. According to research compiled by the company, the global market size for DED is estimated to be worth $7.0 billion in 2024, growing to $12.3 billion by 2032. Earlier this year, Palatin announced the phase 3 clinical results for its PL9643 melanocortin agonist treatment of DED. Regarding the findings, Carl Spana, Ph.D., President and CEO of Palatin, stated, “We are pleased that PL9643 treatment demonstrated excellent safety and tolerability data, including superior efficacy results compared to vehicle across multiple sign and symptom endpoints.” PL9643 represents an opportunity to bring relief to dry eye disease sufferers. According to Palatin, while DED is one of the most common ocular disorders, affecting an estimated 38 million people in the U.S., only about 18 million are diagnosed, and less than 10% of those diagnosed are treated with a prescription product. This shows the significant unmet medical need for an effective treatment with an excellent safety and tolerability profile. There is a sizable market opportunity for the other previously mentioned eye diseases: Palatin’s research states that the 2030 global market estimate for glaucoma is $11.52 billion, and the 2027 global market estimate for retinopathies is $27 billion. Palatin has ongoing melanocortin receptor programs for each disease to explore treatment methods. Treating Autoimmune Diseases There is also a growing opportunity to treat the underlying inflammation in autoimmune diseases that physicians commonly treat with broad immunosuppressants that potentially increase the risk of complications. Palatin Technologies, with an ongoing phase 2 clinical trial, is exploring how its treatments can tackle ulcerative colitis (UC), which the company says could benefit nearly 1 million people in the U.S. who suffer from an autoimmune disease that manifests as chronic inflammation of the colon. Palatin’s research states that the global ulcerative colitis market was estimated to be worth $5.5 billion in 2021 and is projected to be worth $8 billion by 2026. Palatin’s oral MCR1 agonist (PL8177) was developed to resolve inflammation directly in the colon, avoiding broad immunosuppression and adverse effects with its potent, selective compound. Palatin reports that two phase 1 studies have produced promising results – the first demonstrated the significant safety and tolerability of PL8177, while the second highlighted the value of an oral, delayed-release polymer formulation that can achieve local release without systemic absorption. PL8177 has advanced and is now being investigated in a phase 2 clinical trial. Treating Obesity Obesity represents a rising worldwide public health concern. Obesity is associated with an increased risk of overall mortality and serious health conditions, including high blood pressure, high cholesterol, type 2 diabetes, coronary heart disease, stroke and certain cancers. Obesity is associated with increased healthcare resource use and high economic burden. Safe and effective obesity treatments therefore remain a critical unmet need. In the United States, about 42% of adults live with obesity, and one out of five teens between the ages of 12-19 live with obesity, according to data compiled by Palatin. “The growth of GLP-1 agonists to treat obesity has been incredible and highly effective in the short run, but data shows that 67% of patients discontinue use due to side effects and a plateau effect in the first year, said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. “This often results in a rebound effect with patients gaining back significant weight. Our research coupled with emerging clinical data indicates that combining an MCR4 agonist with incretin therapeutics like tirzepatide may result in synergistic effects on weight loss allowing for increased weight loss at lower and better-tolerated doses.” Sexual Dysfunction Product Expansion And Product Development Milestones The success of Vyleesi, which was sold to Cosette Pharmaceuticals in December 2023 for $12 million upfront and up to $159 million in sales milestones, has established a precedent for success in the sexual dysfunction category for Palatin Technologies. Presently, the firm is looking to build on this success and is exploring a product for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i (viagra ®, cialis ® ) monotherapy. According to Palatin, over 30 million men in the U.S. suffer from ED, with approximately 35% of them being inadequately served by existing treatment options. Palatin believes that their MCR4 agonists can be a safe and effective treatment therapy for ED. Across Palatin’s product roadmap, several milestones are slated to occur in the latter half of 2024 or the first half of 2025. Regarding the second half of calendar year 2024, the company’s phase 2 obesity trial of an MCR4 agonist + GLP-1 will initiate enrollment (patient dosing has commenced), Melody-2 and Melody-3 phase 3 clinical trials for the treatment of DED will begin, and the phase 2 proof-of-concept interim data for PL8177 for ulcerative colitis is expected to readout. Regarding the first half of calendar year 2025, the company’s phase 2 obesity trial of an MCR4 agonist + GLP-1 topline results are expected, and the pharmacokinetics study for the clinical program with bremelanotide co-formulated with a PDE5i for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy will start. A Vision For The Future For Millions Of Patients Overall, Palatin Technologies is actively expanding its clinical programs and progressing toward potential new therapies for patients with limited or ineffective treatment options. Melanocortin pathway therapies represent a promising and versatile approach to treating various conditions, with ongoing research and development expanding their potential applications. Palatin Technologies is at the forefront of this treatment approach, potentially helping reshape the medical landscape. For more information about Palatin Technologies, visit its website. Featured photo by Louis Reed on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 08:45 AM Eastern Daylight Time

Image

How This Silver Miner Beat Expectations In Its Recent Earnings Report – And What It Has Planned Next

Benzinga

By Meg Flippin, Benzinga Silver is shining bright this year, with prices up 21% in 2024. It recently hit an 11-year high, and experts are calling for more price increases. That hasn’t been lost on Silvercorp Metals Inc. (AMEX: SVM), the mining company headquartered in Vancouver, British Columbia. The company posted strong first-quarter fiscal 2025 results that it says beat Wall Street expectations, and positioned it for more growth. Silver investors like the metal because it offers diversification beyond stocks and bonds. It tends to increase in price during periods of low interest rates, and with analysts projecting Fed rate cuts, an uptick in silver prices is expected. Just like gold, silver is seen as a store of value. If the U.S. dollar ever devalued, silver could even potentially be used as a form of currency. There’s also a scarcity of it, which means the price has room to appreciate. Much of the silver mined has been used and isn’t recoverable. The global deficit of silver reached an all-time high in 2022 at 237.7 million ounces as the demand for silver rose 18%. Revenue Growing, Costs Declining Silver is Silvercorp’s bread and butter, accounting for 63% of its first-quarter revenue. The company also mines gold, lead, and zinc. For the fiscal first quarter, Silvercorp reported revenue of $72.2 million, up 20% year-over-year, driven by rising silver prices. “The results of this quarter reinforce why investors should own our shares, namely demonstrating that we provide leverage to higher silver prices through the response in our financial results,” said Silvercorp president Lon Shaver during the company’s quarterly results conference call. Silvercorp surpassed Wall Street’s expectations, reporting a net income of $21.9 million, or adjusted earnings of $0.12 per share, up from $9.2 million or $0.05 per share, in the same quarter last year. Analysts had expected the company to weigh in with earnings of $0.09-$0.11 per share. Raymond James also highlighted this strong performance, noting that Silvercorp’s EBITDA of $41 million significantly outperformed their estimate of $26 million, as well as the consensus estimate of $34 million. Cash flow provided by operating activities was $40 million, up 28% year-over-year. Silvercorp ended the quarter with $216 million in cash and short-term investments, another $108 million in equity investments, and zero debt. The company says its results are a testament to its ability to capitalize on market conditions and optimize operations for maximum profitability. Silvercorp’s ability to beat analyst targets on the earnings and cost fronts prompted analysts to reiterate their buy ratings on the stock, with bulls pointing to the strong showing in the quarter, disciplined cost management, healthy cash generations and near-term catalysts as reasons to like the stock. “We largely view the quarter as positive, as the results beat our estimates on the bottom line supported by higher-than-expected realized silver prices, gains on investments and favorable exchange rate movements during the quarter,” wrote Eight Capital in a recent research report. The firm has a buy rating on shares of Silvercorp. Expansion Mode In Full Swing Beyond beating fiscal first-quarter estimates, Silvercorp closed a key acquisition that may serve as a catalyst for the company. In late July, Silvercorp completed its acquisition of Adventus Mining Corporation, creating a geographically diversified mining company. With the acquisition, Silvercorp added the advanced El Domo Project and the exploration stage Condor Project, both located in Ecuador, to its portfolio. Analysts view the move as positive; “For El Domo, we believe it is likely SVM will outline development plans as well as potential improvements to the project which could provide an additional source of positive catalysts in the coming months,” stated Roth Capital in a recent research report. Another potential catalyst is the Mill No. 2 capacity expansion, on track and on budget to be completed by November, which will significantly boost production capacity, Silvercorp reports. The company forecasts the project will increase its total production capacity to around 5,000 tons per day. Silvercorp has accumulated a stockpile of ore ready for processing, and this expansion is expected to increase the company’s output, further driving revenue growth. With silver prices projected to continue rising, and Silvercorp expanding its operational capacity and geographic reach through a strategic acquisition, it could be well-positioned and may offer investors substantial exposure to silver’s likely continued growth. For more information on Silvercorp, please visit silvercorpmetals.com/welcome. Featured photo by Zlaťáky.cz on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 08:45 AM Eastern Daylight Time

Image

Monogram Orthopedics (NASDAQ: MGRM) Readies Commercialization Of Next-Gen Surgical Robot

Benzinga

By Gerelyn Terzo, Benzinga When most people think about robotics, they might envision movies like the popular science fiction film RoboCop. While the entertainment industry put robotics on the big screen, companies like Austin, Texas-based Monogram Orthopedics (NASDAQ: MGRM) are making robotics a reality in everyday life. Monogram is an AI-powered robotics company dedicated to improving human health, including an early specialization in orthopedic surgery. This summer, it has been inching closer to its vision for the commercialization of its surgical robot. According to Virtue Market Research, the orthopedic surgery robotic market was worth $6.8 billion as of 2022 and is predicted to be valued at $16 billion by 2030, reflecting a CAGR of 13%. Monogram could be strategically positioned to capitalize on this growth with its mBôs surgical robot, which it is readying for commercialization, mVision technology and underlying IP. Benzinga recently had the opportunity to sit down with two Monogram surgeons – Dr. Bobby Jamieson and Dr. Fabio Orozco – to discuss the company’s next-generation orthopedic implants harnessing a combination of 3D printing, robotics and pre-operative imaging. Monogram’s 3D Printing Tech Dr. Fabio Orozco, an orthopedic surgeon, runs a medical practice that specializes in hip and knee replacements, with all of his surgeries involving robotics. After completing his training at Thomas Jefferson University in Philadelphia, Pennsylvania, he started a practice in the Northeast that is exclusive to robotics. He told Benzinga he performs 1,000 hip and knee replacements each year. With a very high success rate, hip and knee replacements are a testament to the strong track record of orthopedic surgeons. However, Orozco looks forward to using Monogram’s surgical robots on a daily basis, for, he says, greater precision, better patient care and improved outcomes. “You start thinking about 0.5 millimeters and 0.5 degrees and being able to reproduce your plan exactly to reality in a patient. And then you start seeing rapid recoveries - patients don’t need six months to recover from surgery or don’t need physical therapy. That’s when you see the excitement. We are better when we use technology, and when we use Monogram technology, we continue to be better and better,” said Orozco. Dr. Orozco performs 100% of his surgeries using robotics technology, including approximately 1,000 knee and hip replacements each year. He has been using Monogram’s Mako robot for the past decade, noting that it’s his go-to solution for every hip and knee replacement surgery. Dr. Orozco believes that when Monogram’s next-gen mBôs technologies become a reality, they will take orthopedic surgeries to a different level. “When you bring Monogram to your table, it’s going to make a significant difference in the way that we practice orthopedics,” he said. Chief among the new features that surgeons are anticipating from Monogram is the 3D printing of implants, which replicates the structure of human organs and tissues and can be customized to a patient’s body. Additionally, Monogram says its technology introduces increased precision and ease of use that will simplify robotic surgery significantly. For his part, Dr. Bobby Jamieson has been involved in robotics for years, having studied under the tutelage of orthopedic robotics pioneer and IBM (NYSE: IBM) alum Bill Barger and recently relocated his practice from Northern California to Southern Utah. Jamieson specializes in hip and knee surgeries, completing some 650 of them each year. Upon FDA approval of Monogram’s surgical robot, Jamieson looks forward to introducing the company’s technology to his patients. “I’ve been able to watch Monogram go from zero to where it is today and this is definitely something I’m interested in bringing into the practice once we get the approval on it,” Jamieson said. He also agreed that Monogram is taking orthopedic surgery to the next level. He said that what he appreciates most about the company’s technology is that it takes the best of all robotic platforms available, including features such as navigation, and builds them into a single robot, setting the tech suite apart and drumming up excitement in the industry. Monogram’s Competitive Edge With a market cap of over $90 million, Monogram’s advantage begins with its seasoned team and their strong robotics knowledge. The company’s singular focus on surgical robotic systems can give it a competitive edge against larger corporations that have a broader focus. “Monogram Orthopedics has the advantage is – they eat, drink and sleep robotics, which is awesome,” Jamieson said. “Then you add in 3D printing, and it just allows them to be a little bit further advanced than other surgical robots that are on the market right now.” He compares the precision of Monogram’s surgical robot to that of a driver in a golf game, saying that the tech helps surgeons hit the right spot every time with the ultimate patient-specific knee or hip replacement. That is what Monogram’s robot will deliver, and on top of that, there’s excitement around implants and being able to create the ultimate patient-specific knee or hip replacement for patients, where Monogram is also leading the charge. As Monogram transitions from gen-one to gen-two with its technology. Jamieson likens it to the iPhone, saying that most people wouldn’t even know how to access the first-generation iPhone model today because it’s just so obsolete. “I think that a lot of the robotics are those gen ones. The advantage that Monogram has coming to market is that it’s already at this iPhone five or 10 [level]… they’re able to come in as the newest technology that’s on the market and put it into one robotics system.” In the most recent update, Monogram Orthopedics submitted its 510(k) for its mBôs TKA System to the U.S. Food and Drug Administration (FDA) and has since received administrative approval to proceed with the next step, which involves a formal review. FDA approval is key for orthopedic surgeons to take Monogram’s surgical robots further, including the advancement of the technology on the clinical side. After that, they can begin using it in practice. “It’s an exciting time. It’s also obviously one of the most difficult steps, making sure all the “t’s” are crossed and all the “i’s” are dotted and, for that matter, making sure it’s safe for patients. And so it’s really important and also just exciting,” said Jamieson. Investors who are interested in the future of surgical robotics can learn more about the investment opportunities that Monogram Orthopedics has to offer here. Featured photo by PublicDomainPictures on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 29, 2024 08:30 AM Eastern Daylight Time

Image

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Global Markets News

Nuvectis Pharma (NASDAQ: NVCT) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for its lead candidate, NXP800. This designation, specifically for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, marks a critical step forward in Nuvectis’s mission to address unmet needs in oncology. Orphan Drug Designation: A Strategic Advantage The FDA’s Orphan Drug Designation is awarded to drugs that show promise in treating rare diseases affecting fewer than 200,000 people in the U.S. For Nuvectis, this designation not only validates the potential of NXP800 but also provides several strategic benefits. These include tax credits for clinical trial costs, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. NXP800 targets ARID1a-deficient cancers, a subset of ovarian cancers that present significant treatment challenges. The Orphan Drug Designation underscores the importance of this candidate in potentially offering a new, more effective treatment option for patients with this specific genetic mutation. Background and Market Impact This latest achievement builds on Nuvectis Pharma’s earlier successes. Earlier this year, the FDA granted Fast Track Designation to NXP800 for its development in platinum-resistant, ARID1a-mutated ovarian cancer. The Fast Track status, combined with the Orphan Drug Designation, highlights the urgent need for innovative treatments in this space and positions NXP800 as a potential game-changer in oncology. Financial analysts have taken note of Nuvectis’s progress. H.C. Wainwright recently reiterated its buy rating for Nuvectis, setting a price target of $21. This optimistic outlook reflects the market’s confidence in the company’s strategic direction, particularly as it prepares to release key clinical data later this year. Anticipation for Upcoming Results The next few months are expected to be pivotal for Nuvectis Pharma. The company is poised to share updates from its ongoing Phase 1b clinical trial of NXP800, which targets patients with platinum-resistant, ARID1a-mutated ovarian cancer. This trial is being closely watched, as positive results could significantly advance the development of NXP800, bringing it closer to pivotal trials and eventual regulatory approval. Additionally, Nuvectis is also conducting a Phase 1a dose escalation study for NXP900, its second key candidate, which targets YES1/SRC-driven tumors. Updates from this study are expected to provide further insights into the safety and potential efficacy of NXP900. ### Nuvvectis' Full announcment, titled " Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers" was published on August 29th, 2024. ### This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/fcm9n/pdf. Global Markets News Network is a commercial digital brand compensated to provide coverage of innovative companies and industries and it is thus subject to conflicts of interest. Contact Details Global Markets News News Coverage ronald@futuremarketsresearch.com

August 29, 2024 08:20 AM Eastern Daylight Time

News Release

Railtown AI Technologies (CSE: RAIL) (OTCQB: RLAIF): Leveraging AI to Revolutionize Software Development Efficiency

Railtown AI

The global artificial intelligence (AI) market was estimated at $196.63 billion in 2023 and is expected to grow at a staggering compound annual growth rate (CAGR) of 36.6% from 2024 to 2030, according to Grand View Research. Once seen as the stuff of science fiction, AI has steadily integrated into our daily lives, evolving from a buzzword to a household presence. More importantly, AI is now a cornerstone of modern business, driving efficiencies, cutting costs, and enabling companies to compete in an increasingly digital world. Businesses are harnessing AI in various ways: enhancing cybersecurity, managing fraud, crafting content, and improving customer relationships. A Forbes survey reveals that over half of business owners use AI for cybersecurity, nearly half use it for internal communications, and 64% believe it will strengthen customer relationships. Additionally, 97% of business owners see AI tools like ChatGPT as beneficial to their operations, with many planning to use AI for website content and multilingual communication. Investing in AI stocks has surged as companies across sectors leverage advanced AI technologies to boost productivity and enhance decision-making. This shift is expected to drive revenue and earnings growth in the coming years. With that in mind, it could be the right time to start looking into AI stocks. Now, let’s look at a rising company in this competitive sector. Railtown AI Technologies (CSE: RAIL) (OTCQB: RLAIF) is emerging as a promising player in the AI sector, offering innovative solutions that streamline software development. As a Microsoft Partner, Railtown AI has developed a cloud-based Application General Intelligence (AGI) platform designed to support software developers and Agile teams. The company’s primary focus is to save time on repetitive tasks, improve productivity, reduce costs, and accelerate developer velocity. This platform is readily accessible via Microsoft's Azure Marketplace, making it easily available to a broad range of businesses. What Railtown AI Technologies Does Railtown AI ’s proprietary platform is entirely owned and developed in-house, ensuring that the company has complete control over its technology. The platform is particularly notable for its dual deployment options, catering to organizations with different needs by offering both cloud-based and on-premise solutions. This flexibility, combined with the platform’s ability to process data quickly and learn over time, allows businesses to make real-time decisions and continuously improve their software development processes. The platform’s AI-driven tools target key areas in software development, offering significant benefits. The Root Cause Analyzer detects and alerts developers to errors early, allowing them to resolve issues before they affect users, thereby saving valuable time and reducing costs. The Conductor AI Assistant provides developers with quick, accurate information to solve problems faster, continuously learning from developer feedback to improve its capabilities. The Velocity Dashboard tracks the performance of development teams, helping management make informed decisions on resource allocation and performance management. Additionally, tools like the Release Notes Automator and Ticket Generator automate traditionally manual tasks, further boosting productivity and enabling teams to focus on more strategic work. Why It Matters In a world where software development is increasingly complex and fast-paced, the ability to streamline processes and reduce manual work is critical. Railtown AI’s platform addresses this need by offering tools that not only enhance developer productivity but also ensure higher-quality software. This is particularly important as the industry moves towards Agile practices, which prioritize quick iterations and continuous improvement. By enabling faster and more accurate development cycles, Railtown AI helps organizations stay competitive in a rapidly evolving market. Moreover, Railtown AI's focus on compliance with industry standards such as SOC 2, GDPR, and ISO 27001 is a significant advantage. These compliance achievements build customer trust by ensuring that the platform handles data responsibly and securely. In industries like finance and healthcare, where data protection is paramount, this compliance is not just a nice-to-have but a necessity. As Railtown AI continues to meet these standards, it positions itself as a trustworthy partner for businesses looking to integrate AI into their software processes. The Potential of Railtown AI Technologies Railtown AI has achieved several milestones that indicate its potential for growth. The company recently announced its debt-free status, strengthened its capital base through private placements, and made significant progress in meeting compliance requirements. These achievements, combined with strategic partnerships with leading institutions like the Mila Quebec AI Institute and Amii Alberta Machine Learning Institute, set the stage for future growth. These partnerships are particularly noteworthy as they provide Railtown AI with access to cutting-edge research and development support. For instance, Mila covers 90% of project costs for its research phase with Railtown, while Amii covers 50% of project costs. This financial support, coupled with expertise from PhD candidates and machine learning engineers, enhances Railtown AI ’s ability to innovate and improve its platform. Looking ahead, Railtown AI is poised to capitalize on its compliance achievements by investing in customer acquisition, marketing, and direct sales. The company’s plans to update its patents and explore certification as a vendor for major brands further bolster its growth prospects. As Railtown AI Technologies continues to enhance its platform and expand its market presence, its strategic innovations and strong growth potential make it a compelling stock to watch in the rapidly evolving AI sector. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com

August 29, 2024 06:00 AM Eastern Daylight Time

All Industries

Why You May Want To Consider Linqto As Your Go-To Pre-IPO Investing Platform

Synergist Technology Partners with Microsoft to Drive Ethical and Compliant AI Innovation

Benchmark International Releases Global Semiconductor Machinery Manufacturing Industry Report, Spotlighting Market Growth and Key Trends

Landmark Real Estate Lawsuit Just Changed the Rules – This RE Tech Company May Have The Perfect Solution

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions

How This Silver Miner Beat Expectations In Its Recent Earnings Report – And What It Has Planned Next

Monogram Orthopedics (NASDAQ: MGRM) Readies Commercialization Of Next-Gen Surgical Robot

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Railtown AI Technologies (CSE: RAIL) (OTCQB: RLAIF): Leveraging AI to Revolutionize Software Development Efficiency